Beyfortus proves its effectiveness beyond the first season of VRS

A study published in The Lancet Infectious Diseases reveals that the Beyfortus vaccine (nirsevimab) reduces hospitalizations related to respiratory syncytial virus (RSV) in infants, even beyond their first season. Conducted in Galicia, Spain, the study shows an 85.9% reduction in hospitalizations for lower respiratory tract infections during the first season. A further reduction of 55.3% was observed for the second season in infants who had already been immunized.

Vaccination coverage reached 94.4% among eligible infants. The results, shared in Rome at the RSV conference, also show a direct decrease in consultations for respiratory illnesses.

This study provides strong evidence for the effectiveness of childhood immunization strategies, according to Federico Martinón-Torres, lead researcher. Sanofi emphasizes the significant impact of Beyfortus on public health.